title: BMI changes in adolescents treated with bupropion SR for smoking cessation.
abstract: OBJECTIVE
  Adolescent overweight and obesity and smoking continue to be very important health challenges because of their lasting effects on overall health. Weight gain after smoking cessation is a barrier to quitting as well as a negative consequence to health. This study reports changes in the body mass index (BMI) z-scores of adolescent smokers participating in a dose-ranging clinical trial of bupropion SR (150 mg/day and 300 mg/day) for smoking cessation.
  
  
  METHODS
  A total of N = 296 adolescent smokers (placebo n = 100, 150 mg/day n = 101, 300 mg/day n = 95) with a BMI z-score of 0.5 (sd: 1.4), 0.5 (sd: 1.3), and 0.5 (sd: 1.2) in the placebo, 150 mg/day, and 300 mg/day groups, respectively, were followed for 6 months.
  
  
  RESULTS
  Adolescents in the 300 mg/day group had a significant reduction in BMI z-score 6 weeks after quitting (β = -0.16, CI = (-0.29, -0.04), P-value = 0.01). This result was not sustained at the 6-month follow-up.
  
  
  CONCLUSIONS
  A reduction in BMI z-score during smoking cessation with bupropion has important implications for the future of adolescent smoking cessation. These results are particularly relevant for adolescents who have either overweight or obesity or who have reservations about quitting for fear of gaining weight or BMI.
authors.affiliation: College of Public Health, University of Arizona, Tucson, Arizona, USA.
authors.forename: Lysbeth
authors.initials: L
authors.lastname: Floden
authors.affiliation: College of Public Health, University of Arizona, Tucson, Arizona, USA.
authors.forename: Douglas L
authors.initials: DL
authors.lastname: Taren
authors.affiliation: Department of Family and Community Medicine, University of Arizona, Tucson, Arizona, USA.
authors.forename: Myra L
authors.initials: ML
authors.lastname: Muramoto
authors.affiliation: Mayo Clinic, Phoenix, Arizona, USA.
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Leischow
mesh_terms: D000293:Adolescent; D015992:Body Mass Index; D016642:Bupropion / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D050177:Overweight / Q000150:complications / Q000188:drug therapy; D063766:Pediatric Obesity / Q000150:complications / Q000188:drug therapy; D010919:Placebos; D012907:Smoking / Q000188:drug therapy; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D014029:Tobacco Use Disorder / Q000150:complications / Q000188:drug therapy*
chemical_list: D010919:Placebos; D016642:Bupropion